Atlantic Therapeutics Appoints Former Zeltiq CEO As Chairman

Atlantic Therapeutics has appointed former Zeltiq Aesthetics CEO Gordie Nye as its new chairman to help drive adoption of its CE-marked Innovo device for treating clinical conditions associated with pelvic floor weakness.

Irish device firm Atlantic Therapeutics has named Gordie Nye as its new chairman. The Galway-based company commercializes Innova, an externally applied therapeutic device that delivers electrical stimulation to treat stress urinary incontinence. (Also see "Start-Up Spotlight: Atlantic Therapeutics, Stimulating The Stress Incontinence Market With Vaginal Mesh Alternative" - Medtech Insight, 5 May, 2017.)

Nye is currently CEO of R2 Dermatology, a start-up commercializing an aesthetic dermatology technology from Harvard University. He served as...

Welcome to Medtech Insight

Create an account to read this article

More from Leadership

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By 

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

Execs On The Move: June 30–July 4, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By 

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

More from Medtech Insight

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By 

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By 

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By 

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.